Table 2.
Summary of completed and ongoing clinical trials of oncolytic viral therapies in mesothelioma.
| Identifier | Type of virus | Treatment mode | Integrated transgene/deletion | Status |
|---|---|---|---|---|
| NCT03710876 | Adenovirus | rAd-IFN + celecoxib + gemcitabine | Human IFNα-2b | Recruiting |
| NCT04013334 | Adenovirus | MTG201 + nivolumab | Immortalised cells (REIC)/Dikkopf (Dkk)-3 | Recruiting |
| NCT01766739 | Vaccinia virus | Monotherapy | β-galactosidase, β-glucuronidase, Ruc-GFP | Active, non-recruiting |
| NCT02714374 | Vaccinia virus | GL-ONC1 −/+ eculizumab | β-galactosidase, β-glucuronidase, Ruc-GFP | Active, non-recruiting |
| NCT01997190 | Adenovirus | AdV-tk + valacyclovir + chemotherapy | Herpes simplex virus thymidine kinase (HSV-TK) | Active, non-recruiting |
| NCT01503177 | Measles virus | Monotherapy | Thyroidal sodium iodide symporter (NIS) | Active, non-recruiting |
| NCT02879669 | Adenovirus | ONCOS-102 + pemetrexed/carboplatin | GM-CSF | Active, non-recruiting |
| NCT01569919 | Vaccinia virus | TropVax + pemetrexed/cisplatin | TAA 5TA | Unknown |
| NCT01119664 | Adenovirus | Ad.hIFNα2b + celecoxib + pemetrexed | IFNα2b | Completed |
| NCT00299962 | Adenovirus | Monotherapy | IFNβ | Completed |
| NCT01212367 | Adenovirus | Monotherapy | IFNα-2b | Completed |
| NCT01721018 | HSV-I | Monotherapy | RL1 gene deletion encoding ICP34.5 protein | Completed |
GFP green fluorescent protein, GM-CSF granulocyte-macrophage colony-stimulating factor, HSV Herpes simplex virus, IFN interferon, REIC reduced expression in immortalised cells, TAA tumour-associated antigen.